Crescent Biopharma grants options for 12,525 shares to two non-executive employees as part of an inducement plan.
Quiver AI Summary
Crescent Biopharma, Inc., a clinical-stage biotechnology company focused on advancing cancer therapies, announced that its Compensation Committee approved the grant of options to purchase 12,525 shares to two non-executive employees as part of their employment inducement awards. This decision, made on April 23, 2026, is compliant with Nasdaq regulations and necessary for the employees' acceptance of their roles at Crescent. The options have a 10-year term with an exercise price of $25.70, vesting gradually over time based on the employees' continuous service with the company. Crescent Biopharma aims to develop innovative oncology treatments, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, to provide transformative therapies for cancer patients.
Potential Positives
- Approval of equity inducement awards is a positive step for attracting and retaining talent, indicating the company's commitment to employee incentives.
- The grant of options to employees demonstrates confidence in the company's growth and future potential in the oncology market.
- The inclusion of a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates in the clinical pipeline highlights Crescent's innovative approach and competitive positioning in cancer therapies.
Potential Negatives
- The issuance of equity inducement awards may raise concerns among investors about the company's ability to attract talent without significantly increasing compensation packages.
- The reliance on options grants for employee acceptance could indicate a potential struggle in competitive recruitment within the biotechnology sector.
- The significant amount of options granted could lead to shareholder dilution if the company's stock does not perform well in the future.
FAQ
What equity awards did Crescent Biopharma grant to employees?
Crescent Biopharma granted options to purchase 12,525 shares as equity inducement awards to two non-executive employees.
What is the exercise price for the options granted by Crescent?
The exercise price for the options is $25.70, based on the closing price on April 23, 2026.
How do the options granted by Crescent Biopharma vest?
The options vest 25% after one year, then 1/48th monthly, subject to continuous service with Crescent.
Which employment plan covers the equity inducement awards at Crescent?
The equity inducement awards are granted under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan.
What is Crescent Biopharma's mission?
Crescent Biopharma aims to advance a new wave of therapies for cancer patients through innovative oncology treatments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CBIO Insider Trading Activity
$CBIO insiders have traded $CBIO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CBIO stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT purchased 1,360,000 shares for an estimated $18,237,600
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$CBIO Hedge Fund Activity
We have seen 38 institutional investors add shares of $CBIO stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 2,718,834 shares (+192.2%) to their portfolio in Q4 2025, for an estimated $32,245,371
- FCPM III SERVICES B.V. added 1,677,852 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,899,324
- VESTAL POINT CAPITAL, LP added 1,500,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $17,790,000
- BVF INC/IL added 1,360,900 shares (+98.1%) to their portfolio in Q4 2025, for an estimated $16,140,274
- FAIRMOUNT FUNDS MANAGEMENT LLC added 1,360,000 shares (+98.0%) to their portfolio in Q4 2025, for an estimated $16,129,600
- VR ADVISER, LLC added 745,712 shares (+53.7%) to their portfolio in Q4 2025, for an estimated $8,844,144
- ADAR1 CAPITAL MANAGEMENT, LLC added 606,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,187,160
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$CBIO Analyst Ratings
Wall Street analysts have issued reports on $CBIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 01/21/2026
To track analyst ratings and price targets for $CBIO, check out Quiver Quantitative's $CBIO forecast page.
$CBIO Price Targets
Multiple analysts have issued price targets for $CBIO recently. We have seen 2 analysts offer price targets for $CBIO in the last 6 months, with a median target of $28.5.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $22.0 on 03/02/2026
- Brad Canino from Guggenheim set a target price of $35.0 on 01/21/2026
Full Release
WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 12,525 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on April 23, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to $25.70, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on April 23, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X .
Contact
Amy Reilly
Chief Communications Officer
[email protected]
617-465-0586
